Drugs / Mencevax
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00196950 | Sep → Oct 2003 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00444951 | Feb 2007 → Feb 2008 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00427908 Comparator | Feb → Dec 2007 | meningococcal infection | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00514904 Comparator | Sep 2007 → Sep 2008 | meningococcal infection | GlaxoSmithKline | Completed | Mixed |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-06-22 | GlaxoSmithKline | Regulatory update on divestment of Nimenrix and Mencevax gsk.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mencevax | “Mencevax™ ACWY vaccine” NCT00196950 ↗ |
| Modality | Vaccine | “Mencevax™ ACWY vaccine” NCT00196950 ↗ |
| Route | Subcutaneous | “One Subcutaneous Dose of Mencevax™ ACWY” NCT00196950 ↗ |